ANIP - CIK 0001023024
The table below shows ANI PHARMACEUTICALS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $185.22M | $64.02M | $118.96M | -$31.20M | $3.32M | $15.27M |
| Capital expenditure | $13.84M | $16.24M | $8.87M | $8.88M | $2.56M | $6.13M |
| Investing cash flow | -$34.32M | -$404.72M | -$18.51M | -$15.74M | -$105.48M | -$68.32M |
| Dividends paid | $1.16M | $1.63M | $1.63M | $1.63M | $190.00K |
ANI PHARMACEUTICALS INC reported operating cash flow of $185.22M for fiscal year 2025. That is up 189.3% from $64.02M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $27.47M (FY 2016) to $185.22M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $0.00 |
| Stock buybacks | $12.21M | $10.96M | $4.99M | $1.96M | $890.00K | $1.52M |
| Financing cash flow | -$9.94M | $264.94M | $67.44M | -$5.13M | $194.59M | -$1.44M |